Misleading Supplements

Given the number of companies and individuals willing to profit from fear around neurodegenerative disease, it is necessary to be clear about what not to pursue. The supplement space is particularly vulnerable to exaggerated claims, weak evidence, and biologically implausible mechanisms presented as breakthroughs given the gross lack of regulatory oversight. This section highlights commonly promoted interventions that either lack meaningful evidence, rely on flawed rationale, or have potential downsides. This list is not exhaustive, but it covers several of the most frequently encountered categories.

MCT Oil

Medium-chain triglyceride (MCT) oil is often marketed as a “brain fuel” based on the idea that ketones can substitute for impaired glucose metabolism in Alzheimer’s disease. While this rationale has some biochemical plausibility, the clinical evidence is limited and inconsistent. Small studies have shown modest, short-term cognitive effects in select subgroups, but there is no convincing evidence that MCT oil slows neurodegeneration or meaningfully alters disease course. The effects appear transient and highly dependent on context, and the intervention does not address underlying pathology. At best, MCT oil may act as a short-term metabolic workaround in specific situations, but it is frequently marketed far beyond what the data support.

Ginkgo Biloba

Ginkgo is one of the most widely studied “brain supplements,” but large randomized trials have largely failed to show meaningful benefit in preventing dementia or slowing cognitive decline. Earlier enthusiasm was driven by small or lower-quality studies, while larger, better-controlled trials have been neutral. Despite this, it continues to be marketed aggressively for memory and brain health. The persistence of Ginkgo in the supplement market is a good example of how early signals can be overinterpreted and continue to drive consumer behavior long after stronger evidence has emerged.

Phosphatidylserine

Phosphatidylserine is a normal component of cell membranes and is often marketed as a cognitive enhancer. While it is true that it plays roles in neuronal structure, supplementing it does not appear to meaningfully influence neurodegenerative disease in humans. One important nuance is that phosphatidylserine is also a key “eat-me” signal exposed on the outer leaflet of stressed neurons, marking them for clearance by macrophages and microglia. While this is a normal and essential biological process, it underscores that simply increasing levels systemically does not translate into improved neuronal function and may reflect a misunderstanding of its role. Clinical evidence for cognitive benefit is weak and inconsistent, and claims often exceed the data.

Nootropic stacks

Commercial “nootropic stacks” combine multiple compounds, often with the implication of synergistic cognitive enhancement. These formulations are rarely tested as a whole, and evidence is typically extrapolated from individual ingredients with limited or weak support. The result is a product that appears scientifically grounded but lacks direct, controlled evidence of efficacy. In neurodegeneration, where disease processes are complex and progressive, the idea that a proprietary blend of loosely supported compounds can meaningfully alter outcomes is not credible. These products are better understood as marketing constructs rather than evidence-based interventions.

Detoxes and cleanses

“Detox” products are among the least scientifically grounded interventions in this space. The premise that toxins can be flushed from the brain or body using supplements, teas, or restrictive protocols is not supported by established biology. The body already has well-defined systems for detoxification, primarily the liver and kidneys, and there is no evidence that commercial detox regimens enhance these processes in a way that impacts neurodegenerative disease. In some cases, these approaches can be harmful, particularly if they involve extreme dietary restriction, unregulated compounds, or delay in seeking appropriate medical care.

Hydrogen water

Hydrogen-enriched water is marketed based on claims of antioxidant effects and reduction of oxidative stress. While there are some small experimental and preclinical studies suggesting potential biological effects, the clinical evidence in humans is extremely limited, especially in neurodegenerative disease. The mechanism is not well established at a physiologically meaningful level, and there is no convincing evidence that drinking hydrogen water alters disease risk or progression. This is a clear example of a concept that has been amplified far beyond its evidentiary base.

If there is a supplement you would like covered, contact me!

Sources

Avgerinos, K. I., Egan, J. M., Mattson, M. P., & Kapogiannis, D. (2020). Medium chain triglycerides induce mild ketosis and may improve cognition in Alzheimer’s disease. A systematic review and meta-analysis of human studies.
Alzheimer’s Drug Discovery Foundation / Cognitive Vitality. (2024). Medium Chain Triglycerides (MCTs).
DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., et al. (2008). Ginkgo biloba for prevention of dementia: A randomized controlled trial.
Snitz, B. E., O’Meara, E. S., Carlson, M. C., et al. (2009). Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial.
Alzheimer’s Drug Discovery Foundation. (2023). Phosphatidylserine.
Segawa, K., & Nagata, S. (2022). Dynamics of phosphatidylserine-mediated phagocytosis.
Solomon, T. M., Leech, J., deBros, G. B., et al. (2016). A randomized, double-blind, placebo-controlled, parallel group efficacy study of Alpha BRAIN® administered orally.
Paiva, R., et al. (2024). Adulteration of brain health, cognitive, mood, and sleep dietary supplements.
Klein, A. V., & Kiat, H. (2015). Detox diets for toxin elimination and weight management: A critical review of the evidence.
Ramanathan, D., et al. (2023). Molecular hydrogen therapy for neurological diseases.